Last week, shares of Voyager Therapeutics were purchased at the price of $12.25. Voyager uses gene therapy in fighting neurodegenerative diseases such as ALS, Huntington's, Alzheimers, and others. The company's website can be found here.
We believe the company's management, products, and the market it is in fit nicely within the fund's investment parameters. The fund also to provide some capital to the gene therapy space. We believe this is a market that has a lot of upside.
**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.
No comments:
Post a Comment